Endocrine Abstracts

Abstract unavailable...

Prolactinomas are the most frequent pituitary tumors, and dopamine agonists (DA) are their first-choice treatment, since they normalize PRL levels and reduce tumor size in the majority of patients, by binding to dopamine receptor type 2 (DRD2) on tumoral cells. However, drug resistance occurs in a subset of patients, involving different steps following receptor activation or during the final biological responses. Although resistance to DA has been correlated with a reduced DRD...

Dopamine agonists (DA), mainly cabergoline, are nowadays recommended as the treatment of choice for patients with prolactinomas of any size to lower PRL levels, decrease tumour size, and restore gonadal function. However, some patients do not adequately respond to DA, and resistance to DA may occur in 20-30% of patients treated with bromocriptine and nearly 10-20% of those receiving cabergoline. In these patients, multimodal therapy, including surgery and/or radiotherapy, may ...